Bowen Hanes & Co. Inc. Raises Holdings in Boston Scientific Corporation $BSX

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Bowen Hanes & Co. Inc. raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 13.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 406,060 shares of the medical equipment provider's stock after acquiring an additional 48,995 shares during the quarter. Bowen Hanes & Co. Inc.'s holdings in Boston Scientific were worth $40,963,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of BSX. Colonial Trust Co SC boosted its stake in shares of Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock worth $25,000 after acquiring an additional 260 shares during the last quarter. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific in the fourth quarter worth about $25,000. Sunbeam Capital Management LLC bought a new position in shares of Boston Scientific in the fourth quarter worth about $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific in the first quarter worth about $27,000. Finally, Ameriflex Group Inc. bought a new position in shares of Boston Scientific in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wall Street Zen raised Boston Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, April 29th. Morgan Stanley boosted their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, May 16th. Barclays boosted their price target on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. UBS Group boosted their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Finally, Leerink Partnrs upgraded shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific currently has an average rating of "Buy" and an average target price of $117.50.

Insider Buying and Selling at Boston Scientific

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Up 0.7%

Shares of NYSE:BSX traded up $0.7850 during trading on Friday, reaching $105.9950. 9,396,775 shares of the company were exchanged, compared to its average volume of 6,321,979. The firm has a market capitalization of $157.06 billion, a PE ratio of 63.09, a P/E/G ratio of 2.56 and a beta of 0.66. The business's fifty day simple moving average is $104.10 and its 200-day simple moving average is $102.12. Boston Scientific Corporation has a 12-month low of $78.53 and a 12-month high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's quarterly revenue was up 22.8% compared to the same quarter last year. During the same period last year, the company posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.